LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer

The Leucine Zipper Tumor Suppressor 1 (LZTS1) is a tumor suppressor gene, located at chromosome 8p22, which is frequently altered in human cancer. In normal tissue, its ubiquitous expression regulates cell mitosis by the stabilization of microtubule networks. LZTS1-deficient mouse embryonic fibroblasts have been shown to have an accelerated mitotic progression, and a higher resistance to taxanes, microtubule-stabilizing drugs. We investigate the role of Lzts1 in paclitaxel-resistance in breast cancer cells. Downregulation of Lzts1 expression significantly decreases sensitivity to paclitaxel in vitro. We further analyzed Lzts1 expression by immunohistochemistry in 270 primary breast cancer samples and 16 normal breast specimens. Lzts1 was significantly downregulated in breast cancer samples and its deregulation was associated with a higher incidence of tumor recurrence, and to a worse overall survival. Moreover, Lzts1-negative tumors were associated with unfavorable outcome after taxanes-based therapy. Thus our data suggest that Lzts1 deregulation is involved in breast cancer and its immunohistochemical evaluation may serve as a prognostic factor for breast cancer therapy

[1]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[2]  J. Goodwin,et al.  Decline in the use of anthracyclines for breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Marc E. Lenburg,et al.  Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2011, Breast Cancer Research and Treatment.

[4]  J. Zhao,et al.  Down-regulation of leucine zipper putative tumor suppressor 1 is associated with poor prognosis, increased cell motility and invasion, and epithelial-to-mesenchymal transition characteristics in human breast carcinoma. , 2011, Human pathology.

[5]  L. Esserman,et al.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.

[6]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[7]  Xiaodong Sun,et al.  Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis , 2009, Breast Cancer Research and Treatment.

[8]  N. Samadi,et al.  Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis , 2009, Oncogene.

[9]  C. Hansch,et al.  Taxane Analogues against Breast Cancer: A Quantitative Structure–Activity Relationship Study , 2008, ChemMedChem.

[10]  C. Croce,et al.  Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis. , 2008, Carcinogenesis.

[11]  F. Cognetti,et al.  HER2 and response to paclitaxel in node-positive breast cancer. , 2008, The New England journal of medicine.

[12]  C. Rudin,et al.  Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  W. Robinson,et al.  Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer , 2007, International Journal of Gynecologic Cancer.

[14]  D. Heron,et al.  Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  C. Croce,et al.  Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development. , 2007, Cancer cell.

[16]  L. Mariani,et al.  Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer. , 2005, Cancer research.

[17]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[18]  C. Croce,et al.  Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases , 2004, BMC urology.

[19]  William J. Gradishar,et al.  Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer , 2004, Clinical Cancer Research.

[20]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[21]  K. Uzawa,et al.  Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas. , 2003, International journal of oncology.

[22]  J. Minna,et al.  Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. , 2002, Clinical Cancer Research.

[23]  C. Croce,et al.  FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. , 2002, The American journal of pathology.

[24]  Hansjuerg Alder,et al.  FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. C. Chinault,et al.  Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22 , 2001, Oncogene.

[26]  M. Rugge,et al.  Fez1/lzts1 alterations in gastric carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  C. Croce,et al.  The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  N Kumar,et al.  Taxol-induced polymerization of purified tubulin. Mechanism of action. , 1981, The Journal of biological chemistry.

[29]  P. Schiff,et al.  Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. , 1981, Biochemistry.

[30]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[31]  L. Fallowfield,et al.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  C. Criscitiello,et al.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[34]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[35]  B R Goldspiel,et al.  Paclitaxel (Taxol) , 1994, Pharmacotherapy.